New hope for ulcerative colitis: phase 3 trial launches

This study tests a new medicine called JNJ-78934804 against an existing drug (guselkumab) in 644 people with moderate to severe ulcerative colitis, a chronic condition causing colon inflammation and ulcers. The goal is to see if the new drug can bring about remission—meaning less frequent bowel movements, no rectal bleeding, and a healthier colon lining—at 48 weeks. Participants must have had UC for at least 12 weeks and meet specific disease activity scores.